VirginiaKaklamaniMD
Oncology • San Antonio, TXBreast Cancer, Hematologic Oncology
Professor of Medicine at University of Texas Health Science Center San Antonio
Dr. Kaklamani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
7979 Wurzbach Road
San Antonio, TX 78229Phone+1 210-450-1143Fax+1 210-450-0407- Is this information wrong?
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2000 - 2003
Newton-Wellesley HospitalResidency, Internal Medicine, 1997 - 2000
University of AthensClass of 1996
Certifications & Licensure
TX State Medical License 2014 - 2025
IL State Medical License 2000 - 2017- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2002 Jul 01
- Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2006 May 04
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Join now to see all
Publications & Presentations
PubMed
- Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.Jiang, Y., Ma, D., Jin, X., Xiao, Y., Yu, Y., Shi, J., Zhou, Y., Fu, T., Lin, C., Dai, L., Liu, C., Zhao, S., Su, G., Hou, W., Liu, Y., Chen, Q., Yang, J., Zhang, N., ...> ;Nature Cancer. 2024 Feb 12
- Sequencing therapies: optimal treatment for HR+/HER2- metastatic breast cancer.Kaklamani, V.> ;Clinical Advances in Hematology & Oncology. 2024 Jan 31
- Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.McCann, K., Regan, M., Goldfarb, S., Traina, T., Vidula, N., Kaklamani, V.> ;NPJ Breast Cancer. 2024 Jan 19
- Join now to see all
Lectures
- Genomic stratification with BCI of ER+ early breast cancer patients with limited long-term risk of breast cancer death.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Axillary node metastases with occult primary breast cancerKaklamani V, Gradishar WJ
http://www.uptodate.com/contents/axillary-node-metastases-with-occult-primary-breast-cancer
UpToDate, Wolters Kluwer Health - 2012-08-07
Press Mentions
Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023May 26th, 2023- New Recommendations in Place for Breast Cancer ScreeningsMay 15th, 2023
- 3 Things You Didn’t Know to Ask Your Doctor —Until NowMay 4th, 2023
- Join now to see all
Professional Memberships
- Member
Other Languages
- Greek
Hospital Affiliations
University Health / UT Health Science Center at San AntonioSan Antonio, Texas
CHRISTUS Santa Rosa Health SystemSan Antonio, Texas- St Lukes Baptist HospitalSan Antonio, Texas
- University Health / UT Health Science Center at San AntonioSan Antonio, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
